Author

J. L. Rodriguez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Parker· 1 shared A. Trivette· 1 shared A. Wong· 1 shared B. D. Horning· 1 shared B. F. Cravatt· 1 shared B. J. Doranz· 1 shared C. A. Thorne· 1 shared C. L. Eissler· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. Parker

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Armored Bicistronic CAR T Cells with Dominant-negative TGF-β Receptor II to Overcome Resistance in Glioblastoma.

N. Li, J. L. Rodriguez, Y. Yin, M. T. Logun, S. Yu, K. A. Hicks, V. Zhang, L. Zhang, C. Xie, J. Wang, J. A. Fraietta, Z. A. Binder, Z. Lin, D. M. O'Rourke

This paper develops a tri-modular CAR T cell construct with a dominant-negative TGF-β receptor II to overcome GBM resistance by enhancing T cell function and efficacy in a preclinical model.

bioRxiv · Feb 26, 2024Cancer Biology

Selective inhibitors of JAK1 targeting a subtype-restricted allosteric cysteine

M. E. Kavanagh, B. D. Horning, R. Khattri, N. Roy, J. P. Lu, L. R. Whitby, J. C. Brannon, A. Parker, J. M. Chick, C. L. Eissler, A. Wong, J. L. Rodriguez, S. Rodiles, K. Masuda, J. R. Teijaro, , B. F. Cravatt

This study identifies an allosteric cysteine in JAK1 and TYK2, develops inhibitors targeting it, and shows high subtype selectivity with minimal off-target effects.

bioRxiv · Jan 31, 2022 · PreprintPharmacology & Toxicology

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals

E. C. Chen, P. Gilchuk, S. J. Zost, N. Suryadevara, E. S. Winkler, C. R. Cabel, E. Binshtein, R. E. Sutton, J. L. Rodriguez, S. Day, L. Myers, A. Trivette, J. K. Williams, E. Davidson, S. Li, , J. E. Crowe

The paper identifies public antibody clonotypes in SARS-CoV-2 convalescents and vaccinated individuals, revealing common epitope recognition and potential vaccine efficacy mechanisms.

bioRxiv · May 2, 2021Immunology